



Original Article

ISSN : 2277-3657  
CODEN(USA) : IJPRPM

## *Estimation of Olanzapine and Samidorphan in bulk and Pharmaceutical Dosage Form Using RP-HPL*

Ibrahim Baje Syed<sup>1</sup>, Madhavi Nannapaneni<sup>2\*</sup>

<sup>1</sup>Department of Chemistry, Acharya Nagarjuna University, Nagarjuna Nagar, Guntur, Andhra Pradesh, India.

<sup>2\*</sup>PG Department of Chemistry, JKC College, Guntur, Andhra Pradesh, India.

Email: [jkccollege786@gmail.com](mailto:jkccollege786@gmail.com)

---

### ABSTRACT

A new, simple, responsive, and stable RP-HPLC technique for measuring Olanzapine and Samidorphan's active pharmaceutical components was developed and validated in this study. RP-HPLC technique for the quantitative measurement of Olanzapine and Samidorphan that has been verified and has a well defined stability. Using an Inertsil ODS column with dimensions of 250x4.6 mm and a 5 micron isocratic elution with an acetonitrile/0.1 percent ortho phosphoric acid mobile phase, we developed a chromatographic method (50:50). Instrumental conditions included a stream rate of 1 ml/min and a detection absorbance of 261 nm using the photo diode array detector. To speed up the chromatographic process, an impurity-spiked solution was used instead of water. An international conference on harmonisation (ICH) set rules for validating the proposed approach, which were followed throughout validation. A regression value of  $R^2 > 0.999$  shows the linearity of the calibration charts was within the limit. In test conditions, the suggested approach is rapid, simple, practicable, and reasonably priced. For regular examination of manufacturing samples and for verifying the quality of medication samples during stability studies, it may be used.

**Key words:** Olanzapine, Samidorphan, RP-HPLC, Development, Validation

---

### INTRODUCTION

Atypical antipsychotics like Zyprexa are used to treat schizophrenia and bipolar disorder. Olanzapine is an atypical antipsychotic [1, 2]. It may be used to treat schizophrenia [3, 4] and bipolar disorder [5] during the outset of the illness as well as to keep it under control over the long term. It may be administered orally or intramuscularly. Weight gain, mobility abnormalities [6], dizziness [7] and constipation [8] are some of the most common adverse effects. Low blood pressure [9, 10], Allergy responses [11], neuroleptic malignant syndrome (NMS) [12], excessive blood sugar [13], gynecomastia [14], erectile dysfunction [15] and delayed dyskinesia [16]. It has been shown to increase the risk of mortality in elderly patients with dementia who take it. If used late in pregnancy, there is a chance that the baby may be born with a movement abnormality that will last for some time.

Samidorphan, an opioid antagonist [17], is used to treat schizophrenia and bipolar disorder. Olanzapine-induced weight gain may be mitigated by taking samidorphan in addition to the medication. Mouth-to-mouth samidorphan is used for this purpose. The FDA rejected buprenorphine/samidorphan for the treatment of major depressive disorder because to inadequate proof of efficacy. There are several possible side effects of samidorphan, including drowsiness [18] and gastrointestinal issues [19]. Researchers at Alkermes [20] have looked at the potential of samidorphan to treat alcoholism [21] and cocaine addiction [22], finding that it has comparable effectiveness to naltrexone [23] while having less adverse effects.

**MATERIALS AND METHODS***Chemicals*

Merck India Ltd, Mumbai, India, supplied acetonitrile, HPLC-grade ortho phosphoric acid, and water. Dr. Reddy's laboratory, Hyderabad, supplied APIs of Olanzapine and Samidorphan standards.

*The instrumentation*

This research made use of a Waters Alliance liquid chromatography (model 2695) supervised by a data processing system called empower 2.0 and a light diode array detector (model 2998).

*Method optimization*

Different isocratic and gradient phosphate buffer/acetonitrile mobile phase ratios were examined in order to optimise the chromatographic circumstances. Each experiment, however, used a different mobile phase composition to achieve better resolution and longer acceptable retention durations. The 0.1 percent ortho phosphoric acid buffer and acetonitrile with isocratic elution was used because it resulted in a greater response from active medicinal components. 'Phenomenal and amino - inertsil ODS columns as well as various stationary phases were tested during process optimization". With the inertsil ODS column, which measures 250 x 4.6mm and a PDA detector set at 5, the peak shapes obtained from these tests were satisfactory. Obtaining a high level of sensitivity necessitated setting the flow rate of the mobile phase to 261nm. Retention times for Olanzapine and Samidorphan were around 3.013 and 7.267 minutes, respectively, with a tailing factor of 1.04 and 1.01. Olanzapine and Samidorphan produced 3102 and 6637 theoretical plates, respectively, indicating that the column was a success. Each of the six injections had a relative standard deviation of 0.23 percent to 0.61 percent. By all accounts, the strategy put forward seems to be quite exact. The approach devised was validated in accordance with ICH standards.

*Validation procedure [24-28]*

The International Conference on Harmonisation's Q2 (R1) criteria were used to evaluate the analysis's precision, specificity, accuracy, and linearity.

*Preparation of buffer*

In order to purify 1 Lt of HPLC water, 1 ml of formic acid was dissolved in 0.45 filter paper and the solution was filtered.

*Chromatographic conditions*

On a reverse phase HPLC system, isocratic elution mode was used with an acetonitrile and ortho-phosphoric acid mobile phase, inertsil ODS (250x4.6mm, 5 µm) column at 1 ml/min stream rate.

*Preparation of the standard stock solution*

Sonicate for 10 minutes to completely dissolve the 50 mg Olanzapine and the 50 mg Samidorphan in the 100 ml volumetric flask, then add the rest of the required amount of diluent to make up the 70 ml required for the creation of a standard stock solution.

The typical stock solution is used to dilute 1 ml of the sample in a volumetric flask of 10 ml.

*Preparation of sample solution*

Sonicate for 10 minutes to dissolve Olanzapine and Samidorphan sample in a 100 ml volumetric flask with 70 ml diluents and then add the remaining diluents to get the volume to the mark. A 0.45 mm nylon syringe is used to filter this solution into a device in a vial.

**RESULTS AND DISCUSSION**


The most difficult part of developing a new approach was separating active pharmaceutical components. The chromatographic conditions were fine-tuned in order to get the best results possible.

*System suitability*

A system suitability chromatogram is shown in **Figure 1** together with the injection, USP tailing and plate count values stated in the standard solution.

**Table 1.** Results of system suitability


Parameters of suitability	Acceptance criteria	Drug name	
		Olanzapine	Samidorphan
USP Plate Count	NLT 2000	3102	6637
USP Tailing	NMT 2.0	1.04	1.01
USP Resolution	NLT 2.0	-	10.32
% RSD	NMT 2.0	0.23	0.61



**Figure 1.** Chromatogram of standard

#### Specificity

The interference was examined by analysing each of the test solutions separately, including the placebo, the sample, and the standard. The figure below indicates that the active components and their excipients were clearly separated from the blank and did not interfere with the main peak. As a result, the procedure is particular, as seen in **Figure 2** by a blank chromatogram.




**Figure 2.** Chromatogram of blank

#### Linearity


Olanzapine and Samidorphan were shown to have linearity peaks with areas of 10, 25, 50, 100, 125, and 150 percent, respectively, when tested at various doses. Olanzapine linearity was tested between 15 and 225 µg/ml and Samidorphan linearity was tested between 4 and 60 µg/ml. In every case, there was a correlation coefficient larger than 0.999. Calibration plots are given in **Figure 3** and linearity findings are provided in **Table 2**.

**Table 2.** Linearity results of Olanzapine and Samidorphan

S.no	Conc (µg/ml)	OlanzapineResponse	Conc.µg/ml	SamidorphanResponse
1	12.50	941624	12.50	956383
2	25.00	1806984	25.00	1824638
3	37.50	2613647	37.50	2856572
4	50.00	3538351	50.00	3630360
5	62.50	4432646	62.50	4550920
6	75.00	5341942	75.00	5397679
Correl coef		0.9998		0.99961
Slope		70683.53		71965.24
intercept		17252.32		46525.32



a)



b)

**Figure 3.** Calibration plots of (A) Olanzapine (B) Samidorphan**Accuracy**

Analyzing active pharma component sample solution at 50, 100, and 150 percent concentrations at a specific limit was done in triplicate in this approach. It was determined that percentage recoveries were within the acceptable range. The new method's precision and dependability have been proven. **Tables 3-5** provide the findings.

**Table 3.** Accuracy results


S. No	% Level	Olanzapine % Recovery	Samidorphan % Recovery
1	50	101.2	100.1
2	100	99.9	100.2
3	150	100.6	100.1

*Intraday precision*

Olanzapine (150 µg/ml) and Samidorphan (40 µg/ml) were tested in six duplicates on the same day. Mean, standard deviation, and percent RSD were computed using peak regions. **Table 4** shows the outcomes of this study.

**Table 4.** Intraday precision outcomes

Olanzapine			Samidorphan	
S.No	Conc.(µg/ml)	Response	Conc.(µg/ml)	Response
1	50	3550571	50	3625648
2		3579840		3601256
3		3548354		3648642
4		3514361		3635143
5		3523214		3670474
6		3566521		3684123

**Figure 4.** Chromatogram of sample*Inter-day precision*

Intermediate precision is another name for this level of accuracy. For the purpose of this study, Olanzapine and Samidorphan were tested in six separate samples over the course of one day. The RSD values were discovered to be less than 2%, and the percentage assay values were also found to be near to 100%. **Table 5** summarises the findings of this study.

**Table 5.** Inter-day outcomes of accuracy of Olanzapine and Samidorphan

Olanzapine			Samidorphan	
S.No.	Conc.(µg/ml)	Response	Conc.(µg/ml)	Response
1	50	3592123	50	3637654
2		3548154		3593216
3		3567854		3696241
4		3533215		3687548
5		3578974		3671452
6		3558820		3628543

*LOD and LOQ*

Olanzapine has a LOD of 1.6 µg/ml and a s/n of 6, whereas Samidorphan has a LOD of 1.6 µg/ml and a s/n of 6. Both Olanzapine and Samidorphan have LOQ concentrations of 5 µg/ml and s/n values of 25. The procedure has been validated in accordance with ICH standards.

**Table 6.** LOD and LOQ data

Olanzapine				Samidorphan			
LOD		LOQ		LOD		LOQ	
Conc.	s/n	Conc.	s/n	Conc.	s/n	Conc.	s/n
1.6 µg/ml	6	5 µg/ml	25	1.6µg/ml	6	5µg/ml	25

*Robustness*

Stream rate and the quantity of organic material in the carrier phase were two of the many factors that were put through their paces. Olanzapine and Samidorphan were shown to have robustness that was within the limit in **Table 7**.

**Table 7.** Robustness results of Olanzapine and Samidorphan

Parameter name	% RSD	
	Olanzapine	Samidorphan
FM (0.8 ml/min)	0.72	0.56
FP (1.2 ml/min)	0.90	0.81
Organic minus (45:55)	0.92	1.1
Organic plus (55:45)	1.01	0.44

*Stability*

Room temperature and RT were used for the standard and sample solutions, respectively. Pumping these solutions into the apparatus, the percentage of divergence from initial to 24 h was calculated. There was no substantial variation seen and it was proven that the solutions remained stable up to 24 hours. Olanzapine and Samidorphan medicines have no influence on storage conditions. In the following, you'll find the findings in **Table 8**.

**Table 8.** Stability RT results of Olanzapine and Samidorphan

Stability	Olanzapine		Samidorphan	
	Purity	% of deviation	Purity	% of deviation
Initial	100	0.00	100	0.00
6 h	99.7	-0.30	99.8	-0.20
12 h	99.5	-0.50	99.6	-0.40
18 h	99.4	-0.60	99.3	-0.70
24 h	99.1	-0.90	98.9	-1.10

*Degradation studies*

Samidorphan and Olanzapine samples were put through a series of degrading settings to see whether they could be broken down in any way. Forced degradation studies have been conducted to determine whether the procedure is appropriate for items that have been degraded. As a result of these research, formulations are often tweaked to minimise possible instabilities because of the information they give.

*Acid degradation*

Olanzapine degraded at a 12.2 percent rate in 1N HCl, whereas Samidorphan degraded at a 10.7 percent rate.

*Alkali degradation*

Olanzapine and Samidorphan were degraded at a concentration of 1N NaOH, which resulted in 10.8 and 11.5 percent degradation, respectively.

*Peroxide degradation*

Olanzapine and Samidorphan both degraded at a rate of 13.7% and 15.1%, respectively, when exposed to a solution containing 20 percent hydrogen peroxide.

#### *Reduction degradation*

There was a 10.4 percent Olanzapine degradation and an 11.9 percent Samidorphan decrease in the reduced degradation.

#### *Thermal degradation*

5.9 percent of Olanzapine and 14.1% of Samidorphan were destroyed in the thermal degradation of the sample.

#### *Degradation of hydrolysis*

Olanzapine and Samidorphan were reduced to 0.3 percent and 0.1 percent, respectively, in hydrolysis degradation.

**Table 9** contains the outcomes of all degradations.

**Table 9.** Degradation results of Olanzapine and Samidorphan

Degradation condition	Olanzapine		Samidorphan	
	% assay	%Deg	% assay	% Deg
Acid deg	87.8	12.2	89.3	10.7
Alkali deg	89.2	10.8	88.5	11.5
Peroxide deg	86.3	13.7	84.9	15.1
Reduction deg	89.6	10.4	88.1	11.9
Thermal deg	94.1	5.9	85.9	14.1
Hydrolysis deg	99.7	0.3	99.9	0.1

## CONCLUSION

Samidorphan and olanzapine concentrations may be determined with the use of the well-defined isocratic RP-HPLC method. Stress-induced degradation products and their active pharmaceutical components were well separated and peaks were well resolved from each other, showing that the approach is rapid, simple, practicable, and economical under assay circumstances. A new approach for analysing manufacturing samples and checking the quality of medicine samples during stability studies was developed during stability testing.

**ACKNOWLEDGMENTS :** The author would like to thank all the teacher participants of the study.

**CONFLICT OF INTEREST :** None

**FINANCIAL SUPPORT :** None

**ETHICS STATEMENT :** None

## REFERENCES

1. Roberts RJ, Lohano KK, El-Mallakh RS. Antipsychotics as antidepressants. *Asia Pac Psychiatry*. 2016;8(3):179-88. doi:10.1111/appy.12186
2. Ventimiglia J, Kalali AH, Vahia IV, Jeste DV. An analysis of the intended use of atypical antipsychotics in dementia. *Psychiatry (Edgmont)*. 2010;7(11):14-7.
3. Potkin SG, Kane JM, Correll CU, Lindenmayer JP, Agid O, Marder SR, et al. The neurobiology of treatment-resistant schizophrenia: paths to antipsychotic resistance and a roadmap for future research. *NPJ Schizophr*. 2020;6(1):1. doi:10.1038/s41537-019-0090-z
4. Agarwal P, Sarris CE, Herschman Y, Agarwal N, Mammis A. Schizophrenia and neurosurgery: A dark past with hope of a brighter future. *J Clin Neurosci*. 2016;34:53-8. doi:10.1016/j.jocn.2016.08.009
5. Jann MW. Diagnosis and treatment of bipolar disorders in adults: a review of the evidence on pharmacologic treatments. *Am Health Drug Benefits*. 2014;7(9):489-99.

6. Baizabal-Carvalho JF, Jankovic J. Movement disorders in autoimmune diseases. *Mov Disord.* 2012;27(8):935-46. doi:10.1002/mds.25011
7. Karatas M. Central vertigo and dizziness: epidemiology, differential diagnosis, and common causes. *Neurologist.* 2008;14(6):355-64. doi:10.1097/NRL.0b013e31817533a3
8. Jamshed N, Lee ZE, Olden KW. Diagnostic approach to chronic constipation in adults. *Am Fam Physician.* 2011;84(3):299-306.
9. Hunter BR, Martindale J, Abdel-Hafez O, Pang PS. Approach to Acute Heart Failure in the Emergency Department. *Prog Cardiovasc Dis.* 2017;60(2):178-86. doi:10.1016/j.pcad.2017.08.008
10. Kenny RA, McNicholas T. The management of vasovagal syncope. *QJM.* 2016;109(12):767-73. doi:10.1093/qjmed/hcw089
11. Martín A, Gallino N, Gagliardi J, Ortiz S, Lascano AR, Diller A, et al. Early inflammatory markers in elicitation of allergic contact dermatitis. *BMC Dermatol.* 2002;2:9. doi:10.1186/1471-5945-2-9
12. Sahin A, Cicek M, Gonenc Cekic O, Gunaydin M, Aykut DS, Tatli O, et al. A retrospective analysis of cases with neuroleptic malignant syndrome and an evaluation of risk factors for mortality. *Turk J Emerg Med.* 2017;17(4):141-5. doi:10.1016/j.tjem.2017.10.001
13. Pitton Rissardo J, Fornari Caprara AL. Movement disorders associated with hypoglycemia and hyperglycemia. *Ann Mov Disord.* 2020;3(2):118-20. doi:10.4103/AOMD.AOMD\_18\_20
14. Narula HS, Carlson HE. Gynaecomastia--pathophysiology, diagnosis and treatment. *Nat Rev Endocrinol.* 2014;10(11):684-98. doi:10.1038/nrendo.2014.139
15. Montague DK, Jarow JP, Broderick GA, Dmochowski RR, Heaton JP, Lue TF, et al. Chapter 1: The management of erectile dysfunction: an AUA update. *J Urol.* 2005;174(1):230-9. doi:10.1097/01.ju.0000164463.19239.19
16. Vijayakumar D, Jankovic J. Drug-Induced Dyskinesia, Part 2: Treatment of Tardive Dyskinesia. *Drugs.* 2016;76(7):779-87. doi:10.1007/s40265-016-0568-1
17. Zaveri NT, Journigan VB, Polgar WE. Discovery of the first small-molecule opioid pan antagonist with nanomolar affinity at mu, delta, kappa, and nociceptin opioid receptors. *ACS Chem Neurosci.* 2015;6(4):646-57. doi:10.1021/cn500367b
18. Mullington J, Korth C, Hermann DM, Orth A, Galanos C, Holsboer F, et al. Dose-dependent effects of endotoxin on human sleep. *Am J Physiol Regul Integr Comp Physiol.* 2000;278(4):R947-55. doi:10.1152/ajpregu.2000.278.4.r947
19. Liang Q, Yao X, Tang S, Zhang J, Yau TO, Li X, et al. Integrative identification of Epstein-Barr virus-associated mutations and epigenetic alterations in gastric cancer. *Gastroenterology.* 2014;147(6):1350-62.e4. doi:10.1053/j.gastro.2014.08.036
20. Hillemecher T, Heberlein A, Muschler MA, Bleich S, Frieling H. Opioid modulators for alcohol dependence. *Expert Opin Investig Drugs.* 2011;20(8):1073-86. doi:10.1517/13543784.2011.592139
21. Borges G, Bage CL, Cherpitel CJ, Conner KR, Orozco R, Rossow I. A meta-analysis of acute use of alcohol and the risk of suicide attempt. *Psychol Med.* 2017;47(5):949-57. doi:10.1017/S0033291716002841
22. Page RA, Handley GW. The use of hypnosis in cocaine addiction. *Am J Clin Hypn.* 1993;36(2):120-3. doi:10.1080/00029157.1993.10403054
23. Inagaki TK, Hazlett LI, Andreescu C. Opioids and social bonding: Effect of naltrexone on feelings of social connection and ventral striatum activity to close others. *J Exp Psychol Gen.* 2020;149(4):732-45. doi:10.1037/xge0000674
24. Meftah AM, Deckler E, Citrome L, Kantrowitz JT. New discoveries for an old drug: a review of recent olanzapine research. *Postgrad Med.* 2020;132(1):80-90.
25. Paik J. Olanzapine/Samidorphane: First Approval. *Drugs.* 2021;81(12):1431-6.
26. Mandrioli M, Tura M, Scotti S, Gallina Toschi T. Fast Detection of 10 Cannabinoids by RP-HPLC-UV Method in Cannabis sativa L. *Molecules.* 2019;24(11):2113.
27. Korsakkisok I, Andronopoulos S, Astrup P, Bedwell P, Chevalier-Jabet K, de Vries H, et al. Comparison of ensembles of atmospheric dispersion simulations: lessons learnt from the confidence project about uncertainty quantification. In 19th International Conference on Harmonisation within Atmospheric Dispersion Modelling for Regulatory Purposes; 2020. pp. H19-081.
28. Mishra K, Prasanna KA, Behera SR. Simultaneous estimation of sacubitril and valsartan in bulk and pharmaceutical dosage form by using RP-HPLC. *Res J Pharm Life Sci.* 2020;1(2):25-32.